Adage Capital Partners Gp, L.L.C. Merus N.V. Transaction History
Adage Capital Partners Gp, L.L.C.
- $59.7 Billion
- Q3 2025
A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Merus N.V. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 600,000 shares of MRUS stock, worth $57.6 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
600,000
Previous 833,397
28.01%
Holding current value
$57.6 Million
Previous $43.8 Million
28.87%
% of portfolio
0.09%
Previous 0.08%
Shares
8 transactions
Others Institutions Holding MRUS
# of Institutions
290Shares Held
64.8MCall Options Held
1.65MPut Options Held
758K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$420 Million13.26% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.54MShares$340 Million4.56% of portfolio
-
Commodore Capital LP New York, NY3.53MShares$338 Million21.18% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.05MShares$292 Million5.34% of portfolio
-
Hbk Investments L P Dallas, TX2.85MShares$273 Million3.71% of portfolio
About Merus N.V.
- Ticker MRUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,878,200
- Market Cap $4.4B
- Description
- Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...